Literature DB >> 28228435

Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.

Grace Thompson1, Dominic Pepperell2, Ian Lawrence3,4, Benjamin David McGettigan1.   

Abstract

We report a case of Epstein-Barr virus (EBV)-driven haemophagocytic lymphohistiocytosis (HLH) in a man with Crohn's disease treated with 6-mercaptopurine and adalimumab therapy who was successfully treated with rituximab therapy alone. This is the first published case in an adult patient with EBV-driven HLH in the setting of thiopurine use and inflammatory bowel disease to be successfully treated with rituximab therapy alone. Here, we will discuss putative immunological mechanisms which may contribute to this potentially life-threatening complication. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28228435      PMCID： PMC5337688          DOI： 10.1136/bcr-2016-218578

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  23 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

2.  Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.

Authors:  Ivan J Fuss; Christoph Becker; Zhiqiong Yang; Catherine Groden; Ronald L Hornung; Frank Heller; Markus F Neurath; Warren Strober; Peter J Mannon
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

3.  Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease.

Authors:  C Serrate; M Silva-Moreno; P Dartigues; A Poujol-Robert; H Sokol; N C Gorin; P Coppo
Journal:  Inflamm Bowel Dis       Date:  2009-10       Impact factor: 5.325

4.  XIAP mediates NOD signaling via interaction with RIP2.

Authors:  Andreas Krieg; Ricardo G Correa; Jason B Garrison; Gaëlle Le Negrate; Kate Welsh; Ziwei Huang; Wolfram T Knoefel; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

5.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.

Authors:  Henri Vacher-Coponat; Corinne Brunet; Valérie Moal; Andersen Loundou; Elodie Bonnet; Luc Lyonnet; Sophie Ravet; Emmanuelle Sampol-Manos; José Sampol; Yvon Berland; Françoise Dignat George; Pascale Paul
Journal:  Transplantation       Date:  2006-08-27       Impact factor: 4.939

7.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  Increased IL-16 levels in hemophagocytic lymphohistiocytosis.

Authors:  Hidetoshi Takada; Shouichi Ohga; Yumi Mizuno; Akihiko Nomura; Toshiro Hara
Journal:  J Pediatr Hematol Oncol       Date:  2004-09       Impact factor: 1.289

Review 9.  Infections associated with haemophagocytic syndrome.

Authors:  Nadine G Rouphael; Naasha J Talati; Camille Vaughan; Kelly Cunningham; Roger Moreira; Carolyn Gould
Journal:  Lancet Infect Dis       Date:  2007-12       Impact factor: 25.071

Review 10.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064
View more
  4 in total

1.  Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.

Authors:  Andrew Wisniewski; Julien Kirchgesner; Philippe Seksik; Cécilia Landman; Anne Bourrier; Isabelle Nion-Larmurier; Philippe Marteau; Jacques Cosnes; Harry Sokol; Laurent Beaugerie
Journal:  United European Gastroenterol J       Date:  2019-11-14       Impact factor: 4.623

Review 2.  Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Christopher M Johnson; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2018-09-28

Review 3.  Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease: Case Report and Systematic Review.

Authors:  Bárbara Brambilla; Amanda Machado Barbosa; Cassiano da Silva Scholze; Floriano Riva; Lislene Freitas; Raul Angelo Balbinot; Silvana Balbinot; Jonathan Soldera
Journal:  Inflamm Intest Dis       Date:  2020-03-10

Review 4.  Hemophagocytic Lymphohistiocytosis Secondary to Unknown Underlying Hodgkin Lymphoma Presenting with a Cholestatic Pattern of Liver Injury.

Authors:  A L Booth; P Osehobo; D Rodgers-Soriano; A Lalarukh; M A Eltorky; H L Stevenson
Journal:  Case Rep Gastroenterol       Date:  2018-04-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.